Abstract: The present invention is directed to kappaA (?A) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The ?A conopeptides include unglycosylated and O-glycosylated peptides.

Abstract: The present invention is directed to ?-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the ?-superfamily conotoxin peptides and encoding ?-superfamily conotoxin propeptides, as well as the ?-superfamily conotoxin propeptides.

Abstract: The present invention relates to the use of ?-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid; Xaa6 is any amino acid, Xaa7 is any amino acid, Xaa8 is any amino acid, Xaa9 is des-Xaa9 or any amino acid, Xaa10 is des-Xaa10 or any amino acid, Xaa11 is des-Xaa11 or any amino acid and Xaa2 is des-Xaa12 or any amino acid.

Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.

Abstract: The invention relates to linear ?-carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvillsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.

Abstract: The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.

Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

Abstract: The invention relates to relatively short peptides (termed 1-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.

Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The ?-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

Abstract: The present invention is directed to the new &mgr;O-conopeptides, their coding sequences and their propeptides and to the use of &mgr;O-conopeptides as a local anesthetic for treating pain. The &mgr;O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.

Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

Abstract: Protein disulfide isomerase is a major component of Conus venom ducts. The invention relates to a protein disulfide isomerase (PDI) from Conus snails, a nucleic acid sequence encoding the Conus protein disulfide isomerase, and to methods for folding disulfide-rich peptides using a protein disulfide isomerase. Oxidative folding of conotoxin precursors, catalyzed by a PDI, was more efficient and decreased the number and concentration of transiently accumulated folding species. The PDI-assisted oxidative folding of conotoxins was also influenced by the propeptide relative to the mature peptide.

Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.

Abstract: The present invention relates to the use of &agr;-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid; Xaa6 is any amino acid, Xaa7 is any amino acid, Xaa8 is any amino acid, Xaa9 is des-Xaa9 or any amino acid, Xaa10 is des-Xaa10 or any amino acid, Xaa11 is des-Xaa11 or any amino acid and Xaa12 is des-Xaa12 or any amino acid.

Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

Abstract: The present invention is directed to &bgr;-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the &bgr;-superfamily conotoxin peptides and encoding &bgr;-superfamily conotoxin propeptides, as well as the &bgr;-superfamily conotoxin propeptides.

Abstract: The present invention is relates to a &ggr;-carboxylase from Conus snails, a nucleic acid sequence encoding the Conus &ggr;-carboxylase and to a method for using the nucleic acid or protein sequences for preparing &ggr;-carboxylated proteins.

Abstract: The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.